Articles of Interest

 
STICKY: Global Coronavirus COVID-19 Clinical Trial Tracker

                  

Molnupiravir: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

                  

Paxlovid: Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-

                  

ASHP.org: Assessment of Evidence for COVID-19-Related Treatments

                  

ANTICOAG: Full-dose blood thinners decreased need for life support and improved outcome in hospitali

                  

Monclonal Ab Tx: Regeron FDA EUA Authorization in high risk outpatients

                  

Monclonal Ab Tx: Regeneron: Halts Enrollment of Critically Ill Patients in COVID-19 Antibody Trial

                  

Monclonal Ab: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients

                  

Monclonal Ab Tx: Eli-Lily Ab therapy gets FDA emergency authorization

                  

Baricitinib : FDA Authorizes Baricitinib/Remdesivir Combo for COVID-19

                  

STEROIDS: Coronavirus: Dexamethasone proves first life-saving drug

                  

STEROIDS: Low-cost dexamethasone reduces death by up to one third in hospitalised patients with seve

                  

STEROIDS: Dexmethasone Recovery Trial Data Summary Article

                  

STEROIDS: Dexamethasone in Hospitalized Patients with Covid-19 — NEJM

                  

STEROIDS: Corticosteroids Should Be First Line of Treatment For Severe COVID-19, WHO Says

                  

STEROIDS: Association Between Administration of Systemic Corticosteroids and Mortality Among Critica

                  

Baricitinib : FDA Authorizes Baricitinib/Remdesivir Combo for COVID-19

                  

Remdesivir: Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients (PINETREE STUD

                  

Remdesivir: Compassionate Use of Remdesivir for Patients with Severe Covid-19

                  

Remdesivir: effective against a key enzyme of coronavirus that causes COVID-19?

                  

Remdesivir: Early peek at data on Gilead coronavirus drug suggests patients are responding to treatm

                  

Remdesivir: New data on Gilead’s remdesivir, released by accident, show no benefit for corona

                  

Remdesivir: a randomised, double-blind, placebo-controlled, multicentre trial (China)

                  

Remdesivir: ACTT Trial - NIH clinical trial shows Remdesivir accelerates recovery from advanced COVI

                  

Remdesivir: Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial (WHO/NYTimes)

                  

Tocilizumab NEJM Quick Take: in Covid-19 Pneumonia

                  

Tocilizumab: 2 Arthritis Drugs Reduce Deaths in Very Ill Covid Patients, Study Finds

                  

Tocilizumab: Arthritis Drug Tocilizumab Proves Ineffective In Treating Covid-19, Two Randomized Stud

                  

Tocilizumab: Studies find mixed results for tocilizumab to treat COVID-19

                  

Tocilizumab: Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

                  

Tocilizumab: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, co